Introduction
============

Our daily lives operate on 24-h cycles that are regulated by circadian rhythms. Circadian rhythms synchronize our biological processes, including body temperature, hunger, sleep, gene transcription, and sensory perceptions, to manifest and repeat during specific times each day. The field of circadian rhythm research continues to expand, and it is becoming apparent just how crucial it is to our health to follow these daily rhythms. For example, those in today's constantly working society often experience disruptions in their natural circadian rhythms from nightshifts, jet lag, social jet lag (often experienced by adolescents and high-school students who wake up at an earlier time than their biological clocks demand), and overall short or fragmented nighttime sleep. These disruptions may increase risks of developing cardiovascular disease ([@B46]), cancer ([@B144]), obesity ([@B115]), and metabolic syndrome ([@B151]; [@B43]). Therefore, it is becoming crucial to understand not only how circadian rhythms regulate daily biological processes, but also their molecular framework. Such an understanding may be beneficial to formulating treatment strategies for the above conditions, as well as redefining societal expectations and pressures to work during the biological night.

Human and vertebrate circadian rhythms are synchronized by the master circadian pacemaker, the SCN, which resides in the hypothalamus above the optic chiasm. The SCN entrains circadian rhythms throughout the body, and it does so by receiving light information from the melanopsin-expressing ipRGCs, via the retinohypothalamic tract ([@B68]; [@B77]; see Figure 1 in [@B118]). On a molecular level, the SCN and other cells maintain their own circadian rhythms through feedback loops between canonical circadian clock genes and proteins (here on referred to as "clock" genes and proteins). Clock genes include *Bmal1*, *Clock*, *Per1* and *2*, *Cry1* and *2*, *Npas2*, and *Rev-erb*α, and their protein derivatives BMAL1, CLOCK, PER 1 and 2, CRY 1 and 2, NPAS2, and REV-ERBα ([@B108]; [@B120]). The core circadian feedback loop formed from interactions between these genes and proteins is as follows: CLOCK and BMAL1 bind to the promoter regions of *Per* and *Cry*, initiating transcription of these genes; the protein products, PER and CRY, form a complex that enters the cell's nucleus and represses the transcriptional activity of CLOCK and BMAL1, subsequently stopping *Per* and *Cry* transcription ([@B108]; [@B120]). This loop repeats every 24 h. Each step of the loop is synchronized (entrained) to a specific time point. Light and other environmental cues entrain each circadian mechanism to a specific ZT ("time giver"). Without light or other external cues, the internal clock oscillates on what is called CT. CLOCK and BMAL1 also target the promoter regions of other genes, which drive other circadian feedback loops and biological processes, depending on the cell. Along with the SCN, other neuromodulators contribute to the proper cycling of clock genes and proteins, which overall keeps these biological processes running on time.

Dopamine, a neurotransmitter well known for regulating movement, reward, and learning, is emerging as one of the neuromodulators of central and peripheral circadian rhythms. Studies of both the SCN and peripheral brain areas have shown explicit and potential evidence of DA modulating, or being modulated by, neuronal clock genes, proteins, and rhythms. This review focuses on five of those brain areas: the retina, OB, striatum, midbrain, and hypothalamus (See Supplementary Table [1](#SM1){ref-type="supplementary-material"}).

Dopamine is a well-known modulator of circadian rhythms in the retina. In particular, the circadian release of vertebrate retinal DA (either endogenously expressed in the interplexiform, amacrine, or both cells, depending on the species) allows for proper light adaptation and transmission of light information to the SCN, via the melanopsin-expressing ipRGCs ([@B68]; [@B77]; [@B133]; [@B134]). The neuronal circuitry of the retina is morphologically similar to that of the OB, and the OB also expresses DA in the glomerular interneurons. Our lab has found a diurnal variation in DA release in the OB ([@B38]), which may suggest that DA is involved in neuromodulation of OB circadian rhythms (see [@B118]). In the dorsal striatum, dopaminergic input is required for proper modulation of PER2 ([@B82]), and DA receptors regulate clock gene expression in the striatum *in vitro* ([@B86]). Additionally, TH (the rate-limiting enzyme in DA synthesis) has diurnal variation in the striatum and dopaminergic projecting neurons from the midbrain ([@B165]), and TH is also regulated by clock genes in the midbrain ([@B114]; [@B165]; [@B34]; [@B150]). Lastly, we include the hypothalamus because it houses the SCN and because of its circadian-controlled homeostatic functions, including the circadian-like modulation of PRL release by the dopaminergic tuberoinfundibular neurons ([@B62]; [@B18]). This review does not explore DA modulation of circadian rhythms in the hippocampus. However, the hippocampus' circadian clock may be involved in mood regulation and neurogenesis (see review by [@B113]), which can be potential targets of DA's mesolimbic pathway.

To validate the importance of DA to circadian rhythms in humans and rodents, the neurodegenerative disorder, PD, is also explored. Affecting millions worldwide, PD destroys dopaminergic neurons of the SNc, leading to common motor symptoms (e.g., bradykinesia, rigidity, tremor) ([@B28]). Among classes of DA receptors, D~1~ and D~2~ receptors play a central role in the pathogenesis of PD ([@B162]). Dysfunction of dopaminergic populations in brain regions including the midbrain, striatum, retina, OB, and hypothalamus also may lead to other circadian symptoms of PD such as altered locomotor activity ([@B60]), sleep disturbances ([@B157]; [@B54]; [@B105]; [@B30]; [@B104]; [@B162]), visual dysfunction (see [@B7]; [@B30]; [@B133]), olfactory dysfunction/hyposmia ([@B49]; [@B84]; [@B140]; [@B102]; [@B48]), and disruptions to cyclic PRL release ([@B122]; [@B13]; [@B166]). Recent evidence suggests that PD may affect circadian rhythms and their cellular mechanisms differently in the peripheral hypothalamus than in the SCN ([@B73]; [@B101]; [@B78]; [@B111]).

Dysregulation and alterations in circadian genes are commonly observed in people and animal models with PD ([@B27]; [@B101]; [@B78]; [@B5]). Oxidative stress, a potential inducer of PD, may be regulated by clock genes (see [@B5]). *Per1* and *Per2* regulate cAMP activity, which regulates the AHr ([@B5]). A dysregulation of cAMP, potentially through the desynchronization of *Per1* and *Per2*, can lead to an AHr-induced reduction in melatonin synthesis ([@B5]). A decrease in melatonin, which is an antioxidant, can lead to mitochondrial dysfunction and atrophy of SNc's dopaminergic neurons ([@B5]), potentially leading to PD-like symptoms.

In regard to studies of PD, it should be noted that limitations to various animal models of this disease exist (see [@B60]). For example, most transgenic mouse models of PD do not show a selective and/or progressive neurodegeneration of DA neurons ([@B40]). In addition, the acute nature of the insult on DA neurons in neurotoxin-based models differs from the slow, progressive, age-dependent neurodegeneration of DA neurons seen in PD ([@B109]; [@B31]). Thus, many of these models lack the key motor and non-motor disruptions observed in PD patients (see [@B60]). That being said, data from studies using animal models of PD are included in this review to fill gaps in data from human studies.

The study of DA as a neuromodulator can provide additional understanding to what is already known about the molecular and neuronal mechanisms that drive the circadian rhythms of the brain and other areas. Furthermore, this knowledge could lead to pharmacological therapies aimed at correcting abnormal neuronal mechanisms in those with disrupted circadian rhythms, and, potentially, pharmacological therapies to alleviate symptoms of PD.

Retina
======

The retina (see Figure 1 in [@B133]) is the first region of the nervous system to receive and process light, before sending the visual information to the rest of the brain. The retina supplies light information to the SCN via the retinohypothalamic pathway, and it is critical for entrainment of the body's circadian rhythms ([@B68]; [@B77]). The neurons of the retina, as those of the OB, can also maintain the synchrony of their circadian rhythms independent of the SCN ([@B52],[@B53]; [@B72]; [@B141]; [@B92]), and DA has been directly linked to the regulation of circadian rhythms of retinas *in vitro* ([@B52],[@B53]; [@B141]).

Daily Rhythm of Retinal Dopamine Content Depends on Retinal Melatonin
---------------------------------------------------------------------

The mammalian and fish retinas have a daily rhythm of DA content, which peaks during the daytime hours and falls during the nighttime hours ([@B52],[@B53]; [@B136]). This retinal DA rhythm appears to be dependent on melatonin, a hormone that helps to induce sleep during darkness ([@B52]). In the [@B52] study, a mouse strain (C57BL/6J) was used that was unable to produce endogenous melatonin, and, as a result, the circadian rhythm of retinal DA levels was lost in constant darkness. With the application of exogenous melatonin to the mouse retina, DA rhythmicity in constant darkness was restored ([@B52]). Thus, there may be a mutual inhibition between DA and melatonin, which leads to daily rhythmicity in the retina ([@B88]; [@B25], [@B26]; [@B52]).

On the other hand, the rhythm of DA content in the retina may not depend on the integrity of the retina's photoreceptor cells ([@B53]). The rat strain RCS/N-*rdy*, whose photoreceptors degenerate after 18 days of age, had an unaltered daytime rhythm of DA, both in 12-h light/dark cycles and in constant darkness ([@B53]). In the absence of photoreceptors, the unaltered rhythmicity of retinal DA may be entrained by ipRGCs, as these cells send glutamatergic signals to postsynaptic dopaminergic cells ([@B134]). This [@B53] study also confirmed that retinal contents of DA and its metabolites are higher during the daytime rather than nighttime. This finding is consistent with that of [@B42], who showed that postmortem human retinas had higher DA concentrations when the person died during the daytime rather than the nighttime ([@B42]). This is also consistent with the finding that light increases retinal TH activity and DA turnover in the rat retina ([@B89]).

Dopamine Receptors' Vast Effects on Retinal Light Adaptation and Circadian Rhythms
----------------------------------------------------------------------------------

The vertebrate retina expresses two classes of DA receptors: D~1~-like receptors (which includes D~1~ and D~5~ receptors) and D~2~-like receptors (which includes D~2~, D~3~, and D~4~ receptors, although D~3~ may not be present in the retina) ([@B167]; [@B133]). D~1~ receptors are found on horizontal, amacrine, and bipolar cells, while D~5~ receptors are found in the retinal pigment layer ([@B167]). Some of the D~2~ receptors function as autoreceptors for DA neurons, while D~4~ receptors are found on rods and cones photoreceptors, at least in mice ([@B167]).

Evidence suggests that the D~1~ receptor, but not the D~2~ receptor, influences the PER2 protein of the retina. Exposing mouse retinal explant cultures to 1-h pulses of light during CT 13 and CT 19.5 (retinal subjective night) delays retinal PER2 expression by 2.3 h at CT13 and by 1.5 h at CT 19.5 ([@B141]). The *in vitro* expression of retinal PER2 is also affected by the D~1~ receptor antagonist, SCH-23390, and a 1-h pulse of light at CT 13 ([@B141]). SCH-23390 applied during the 1-h light pulse decreased the PER2 expression delay significantly compared to the effects of light exposure alone ([@B141]). Without light exposure, application of the D~1~ receptor agonist, SKF38393, at CT 13 induced a delay of PER2 expression by 1 h ([@B141]). Conversely, activating the D~2~ receptor with the agonist quinpirole, applied at CT 13, does not affect the timing of the PER2 expression ([@B141]).

Activation of the D~2~ receptor induces *Per1* transcription through the recruitment of the CLOCK:BMAL1 heterodimer, an action that was shown to be specific to neurons ([@B168]). The D~2~ receptor also may regulate the rhythmic transcription of melanopsin mRNA in ipRGCs ([@B143]), possibly influencing light entrainment signals being sent to the SCN. Additionally, DA appears to inhibit the activity of melatonin and aralkylamine *N*-acetyltransferase (AA-NAT, also known as serotonin *N*-acetyltransferase), a key enzyme in the production of melatonin ([@B88]; [@B25]). This inhibition was shown to be mediated through the D~2~ receptor, because D~2~ agonists, such as LY171555 and quinpirole, mimicked DA's inhibition of AA-NAT activity ([@B88]) and melatonin release ([@B25]) and also mimicked the effects of light exposure ([@B88]; [@B25]).

Without retinal DA, cone-driven light adaptation (indicative of nighttime to daytime transition), contrast sensitivity, and visual acuity decrease ([@B91]). Dopaminergic modulation of these retinal functions appears to be largely through the activity of D~1~ and D~4~ receptors ([@B91]). Both receptors appear to increase the light-adapted amplitude of a b-wave (representative of ON-bipolar cell functionality); however, visual acuity appears to only be impacted by D~1~ receptors, and contrast sensitivity, by D~4~ receptors ([@B91]; [@B85]). Daytime contrast sensitivity, in turn, is also regulated by RGCs that express the clock protein NPAS2 ([@B85]). Interestingly, DA, through activation of the D~4~ receptor, influences the proper expression of the *Npas2* gene, and regulates contrast sensitivity ([@B85]). The activation of NPAS2 likely drives the activity of RGC's AC1 ([@B85]). Support for this hypothesis comes from the finding that expression of the D~4~ receptor gene, *D4d* (which fluctuates on a circadian rhythm similar to that of retinal DA), is necessary for the expression of *Adcy1*, a gene that produces AC1 ([@B90]). This was confirmed with pharmacological manipulation, where the D~4~ antagonist, L745870, decreased the daytime expression of *Adcy1* ([@B90]). Therefore, activation of the D~4~ receptor, during the daytime, is required for rhythmic fluctuation of cAMP through the regulation of AC1, and thus, contrast sensitivity and other downstream effects of the second messenger system ([@B90], [@B91]; [@B85]).

Recent additional evidence also suggests that D~4~ receptors are involved in light adaptation ([@B134]). Melanopsin-containing M1 ipRGCs, involved in sending light information for circadian photoentrainment ([@B68]; [@B77]), have been shown to presynaptically activate dopaminergic amacrine cells ([@B134]). Mice without viable M1 ipRGCs have impaired light adaptation, which was rescued by the D~4~ receptor agonist, PD168077 ([@B134]). D~4~ receptors expressed on cone photoreceptors ([@B167]) allow for proper presynaptic feedback from active M1 ipRGCs and DA amacrine cells and optimal light adaptation ([@B134]).

Dopamine's Modulation of Retinal Gap Junction Channels
------------------------------------------------------

The retina is rich in gap junctions, which contribute to different retinal functions by coupling (opening) and uncoupling (closing) to allow and block fast current transmission between retinal neurons. Some of these functions may be to set the period of retinal oscillators ([@B92]). Layers of the mammalian retina *in vitro* were found to have different oscillators, which oscillate on a 26-h period ([@B92]). This independent oscillation was shown to be due to gap junction coupling between the retinal layers ([@B92]). One of the layers that expresses an independent period is the inner nuclear layer ([@B92]), which contains the dopaminergic amacrine cells.

Retinal AII amacrine cells, which are important for rod photoreceptor-mediated vision, adapt to light environments by communicating with neighboring AII amacrine cells through the gap junction channel Cx36 ([@B100]). The uncoupling mechanism of retinal Cx36 channels is modulated by DA, released from neighboring amacrine cells ([@B100]). This effect is mediated by DA's action on the D~1~ receptor, which activates the following intracellular mechanism: D~1~ receptor's Gα~S~ protein activates AC and PKA, which phosphorylates protein phosphodiesterase 2 A, which dephosphorylates the serine 293 residue of the Cx36 channel, effectively uncoupling and shutting the channel ([@B100]). This mechanism blocks off communication between neighboring amacrine AII cells ([@B100]). Since DA uncouples amacrine cells' Cx36 gap junctions by activating the above-described D~1~ receptor-driven mechanism ([@B100]), it may be that another D~1~ receptor-driven mechanism could set the phase of PER2 in amacrine and other retinal cells ([@B141]; [@B92]).

In the fish retina, horizontal H1 cells are also coupled via gap junction channels, which the D~1~ receptor also uncouples during the day ([@B136]). An interesting observation from this study was that these gap junctions were coupled to each other in constant darkness (during the subjective day and subjective night) ([@B136]). This implies that the circadian-driven DA release was not enough to uncouple these gap junctions, because either photopic light or the D~1~ receptor agonist SKF38393 was required to significantly uncouple these gap junctions ([@B136]). This may be due to the fact that, unlike D~2~-like receptors, D~1~ receptors are less sensitive to DA, and the DA release during the circadian subjective day was too low to surpass the threshold for D~1~ activation and gap junction uncoupling ([@B136]). However, because D~2~-like receptors are more sensitive to DA, then the circadian-driven DA release could be enough to regulate gap junctions of other cells ([@B136]).

In the photoreceptor layer, the D~2~-like D~4~ receptors regulate the coupling of gap junctions between rod and cone photoreceptors ([@B135]; [@B103]; [@B93]; [@B170]). Unlike the fish horizontal H1 cells, the gap junctions between the fish photoreceptors were able to couple during the subjective night and uncouple during the subjective day ([@B135]). The uncoupling of these gap junctions is mediated by D~2~-like receptor activation, both in fish and mouse retinas ([@B135]). Increased nighttime coupling (when DA levels are low) would, therefore, increase rod-driven dim light transmission through other rods and cones ([@B135]). This nighttime transmission would increase the signal-to-noise ratio of transduction of dim light, but coupled rods' response to single-photons would be decreased ([@B93]). It has been confirmed that the gap junction channel between these photoreceptors is Cx36, mediated by D~4~ receptors, which uncouple Cx36 through inhibition of the AC/PKA pathway ([@B103]). Interestingly, adenosine and its receptor, A2aR, which also have rhythmic expression, appear to increase the nighttime coupling of photoreceptor Cx36 by activating the AC/PKA pathway ([@B103]). Finally, it was confirmed that Cx36 channel phosphorylation (leading to coupling) fluctuates on a circadian scale and that photopic light decreases Cx36 phosphorylation ([@B170]). These studies show that DA influences the gap junction uncoupling through several layers of the retina, both in fish and mice. Uncoupling of the photoreceptor gap junctions via D~4~ may influence the contrast sensitivity of the retina, while uncoupling through D~1~ receptors may influence the visual acuity ([@B91]).

The Co-release/Co-transmission of DA and GABA in the Retina
-----------------------------------------------------------

Retinal amacrine cells have been shown to release both DA and γ-amino butyric acid (GABA) ([@B80]), although it is not clear whether these two neurotransmitters are co-released (same synaptic vesicle) or co-transmitted (same neuron, but different synaptic vesicles) ([@B159]). GABA proves to be important in the regulation of retinal circadian rhythms, because it decreases the amplitude of PER2 levels in the retina in a dose-dependent manner ([@B141]). Because retinal GABA is an important neurotransmitter in modulating the clock proteins of the retina ([@B141]), then GABA release by dopaminergic neurons in the OB ([@B110]; [@B98]; [@B94]; [@B107]), the midbrain ([@B156]; [@B33]), and the hypothalamus ([@B169]) may also be important in the modulation of circadian-like activities.

Parkinson's Disease and the Retina
----------------------------------

Patients with PD have a number of types of visual dysfunction, some which may relate to altered retinal DA levels (see [@B7]). Studies have shown that PD patients have thinner inner retinal layers, where endogenous dopaminergic amacrine cells reside (specifically, in the inner plexiform layer) ([@B167]; [@B74]; [@B2]; [@B152]). Disruptions of retinal dopaminergic neurons resulting in reduced retinal DA levels ([@B126]; [@B76]) may contribute to visual symptoms such as impaired foveal vision ([@B19]), contrast sensitivity ([@B24]; [@B133]), and light adaption ([@B134]) in patients with PD ([@B7]). Impaired color and contrast discrimination may be a preclinical signs of PD ([@B30]).

Decreased retinal DA levels in PD patients also have potential implications to circadian function. In mammals, photic entrainment of circadian rhythms occurs when ipRGCs convey photic signals to the SCN via the retinohypothalamic pathway ([@B68]; [@B77]). DA has been shown to regulate rhythmic melanopsin mRNA expression of these ipRGCs, possibly via actions at D~2~ receptors ([@B143]). Dopaminergic amacrine cells in the retina also express circadian rhythms in expression of clock genes ([@B47]).

Olfactory Bulb
==============

The first region of the nervous system to receive and process odorant information is the mammalian OB (see Figure 11 in [@B99]). Chemical odorants activate OSNs in the olfactory epithelium, which transmit odor signals to neurons in the GL of the OB. Synaptic contact between the OSNs and OB neurons occurs in discreet spherical structures known as glomeruli, where OSNs form glutamatergic axodendritic synapses with the main OB output neurons, mitral and tufted cells (M/TCs) ([@B17]; [@B57]), as well as local interneurons ([@B56]). Surrounding the glomeruli, three morphologically distinct populations of interneurons exist: PGCs, SACs, and ETCs ([@B67]; [@B147]; [@B148]; [@B124]). Collectively, these interneurons are known as JGCs. In addition to having synaptic contacts with each other, JGCs target both OSN terminals and M/TCs ([@B147]; [@B83]; [@B16]; [@B56]; [@B39]; [@B124]). Dopaminergic OB neurons are JGCs that are found in the GL ([@B10]; [@B56]; [@B98]). An estimated 11% (∼87,000 neurons) of JGCs in the mouse OB are dopaminergic ([@B129]), while the adult rat has an estimated 100,000--150,000 dopaminergic neurons in the GL ([@B117]). DA receptors are found throughout the entire OB, with D~1~ receptors localizing in all layers but the ONL, and D~2~ receptors heavily localizing in the GL and ONL ([@B127]; [@B83]; [@B16]; [@B56]; [@B39]).

As in the retina, the OB has been shown to have circadian rhythms that are independent of the master circadian pacemaker, the SCN, allowing the OB to maintain its daily rhythmicity *in vitro* ([@B70],[@B71]). However, the neuronal mechanisms that drive the independent circadian activity of the OB are not well known. DA, which has a daily rhythm of release in the rat OB ([@B38]), may be involved in modulating the circadian activity of the OB via a variety of mechanisms (and DA itself may be regulated through circadian mechanisms) ([@B118]).

Daily Dopamine Activity in the Olfactory Bulb
---------------------------------------------

In the rat OB, DA content rhythmically fluctuates depending on the light cycle ([@B38]). The overall activity was determined by measuring the ratio of DA's metabolite, DOPAC (representative of DA release), to DA every 2.5 ZT hour ([@B38]). DOPAC/DA ratios were shown to be highest during ZT 0-12 (lights turned on) and lowest during ZT 13-24 (lights turned off) ([@B38]). Since DA release follows a diurnal variation, it may be that circadian activity in the OB also occurs in dopaminergic neurons ([@B118]).

Dopamine's Presynaptic Inhibition of Olfactory Sensory Neurons
--------------------------------------------------------------

An abundance of electrophysiological data has shown that DA, released by JGCs, presynaptically inhibits transmission between OSNs and OB neurons by activating D~2~ receptors on OSN terminals ([@B83]; [@B16]; [@B56]). A subsequent study by our group showed that DA also inhibits excitatory transmission between M/TCs and interneurons by a presynaptic mechanism involving D~2~ receptors ([@B39]). In addition, DA also induces excitation in postsynaptic interneurons via the D~1~ receptor ([@B107]). Through these actions, and the diurnal release of DA, it is hypothesized that DA sharpens synaptic processing of olfactory information by diminishing tonic odorant noise ([@B16]; [@B56]).

Since OSNs and M/TCs excite their postsynaptic targets via glutamate release, DA's presynaptic inhibition decreases the release of glutamate onto postsynaptic targets, effectively keeping them from becoming excited and transmitting the odor signals to higher brain regions ([@B83]; [@B16]; [@B56]). Inhibition by DA appears to be presynaptic, because application of exogenous DA did not change the kinetics of the postsynaptic response of M/TCs to olfactory nerve stimulation, indicating that both NMDA and AMPA/kainate receptor-mediated components were affected equally ([@B16]). Also, DA did not directly affect currents evoked by exogenous application of glutamate to cultured OB neurons ([@B16]; [@B39]). Further supporting a presynaptic mechanism, DA altered the ratio between the conditioning and the test response amplitude recorded in postsynaptic neurons in rat OB slices, thereby attenuating the degree of paired-pulse depression ([@B56]).

Dopamine May Act as a High-Pass Filter for Olfactory Bulb Signal Transduction
-----------------------------------------------------------------------------

All neurons that store and release chemical neurotransmitters via vesicular exocytosis have the potential to deplete their vesicular storage with a high-frequency stimulus. Conversely, neurons may not release any vesicles if the signal is too low in frequency. Most neurons are gated to a specific frequency that would allow for vesicular exocytosis. Therefore, neurotransmitters that are released by low-frequency, but not high-frequency, stimuli are regulated by a low-pass filter, while neurotransmitters that are released by high-frequency, but not low-frequency, stimuli are regulated by a high-pass filter. The release of DA in the OB may be gated by a low frequency, suggesting that a low-pass filter is needed for DA release. However, DA itself may influence OB signal transduction as a high-pass filter.

Theta frequency (4--10 Hz), which is observed in the OB's GL ([@B63]), may be needed to release DA and other neurotransmitters. Theta frequency is also implied to be the sniffing frequency at which rodents sample odors ([@B164]; [@B107]; [@B65]), and this low frequency could also increase the signal-to-noise ratio. Therefore, if OB DA is released while sniffing at a theta frequency, DA release may inhibit low, tonic odor transmission. If a nocturnal animal is sampling odors while awake (when OB DA content is low), or while asleep during the day (when OB DA content is high), potent odors may activate dopaminergic interneurons so frequently that eventually the vesicular DA storage will be depleted. Additionally, constant DA release and binding can desensitize the presynaptic D~2~ receptors on OSNs ([@B12]; [@B35]). Constant D~2~ receptor activation would lead to phosphorylation of these receptors by G-protein receptor kinases, which would recruit the arrestin proteins, eventually leading to an internalization of the receptor ([@B12]; [@B35]). Thus, DA release may be gated by a low-pass filter, but DA activity, itself, may act as a high-pass filter, allowing for only those odors that surpass a threshold to be transmitted.

Dopamine and GABA Co-release in the Olfactory Bulb
--------------------------------------------------

In the OB, nearly 97% of all DA JGCs co-express glutamate decarboxylase 67, the rate-limiting enzyme in GABA production ([@B94]), indicating that GABA is released from DA cells ([@B110]; [@B98]; [@B21]; [@B107]). It is interesting to note that even though there are species differences between the chemical composition of rat and mouse OB JGCs, the dopaminergic neurons of both species largely co-express GABA ([@B96], [@B99]). One of the JGCs that co-expresses DA and GABA is the SAC ([@B81]; [@B97]; [@B94]; [@B107]). Evidence suggests that SACs release both GABA (inhibition through GABA~A~ receptor) and DA (excitation through D~1~ receptor) onto neighboring and distant glomeruli, generating a biphasic inhibition-excitation response ([@B107]).

The DA-GABA co-release mechanism may be linked to a rodent's sampling rate of novel odors ([@B107]). SACs form synapses with ETCs, which release glutamate onto all other OB interneurons and the main output cells, M/TCs ([@B107]; [@B124]). GABA and DA, co-released from SACs, lead to a temporal, biphasic inhibition-excitation response in ETCs ([@B107]), which facilitates or dampens the transmission of olfactory signals to higher brain regions ([@B107]). A feed-forward inhibition of M/TCs also would occur when some ETCs activate GABAergic PGCs ([@B107]). These GABA and DA actions may indirectly allow some M/TCs to send odor signals, while other M/TCs are briefly inhibited. Therefore, a rodent may process important odors (e.g., predators, food) more selectively while it is sleeping during the day, which is when OB DA activity is reported to be highest ([@B38]).

Biophysical Properties and Daily Expression of the Connexin 36 in the Olfactory Bulb
------------------------------------------------------------------------------------

As in the retina, Cx36 gap junction channels are expressed in the OB ([@B14]; [@B32]) and play a crucial role in the transmission of the odorant signals in the OB within the mitral cells ([@B32]). Specifically, mitral cell dendrites couple to each other in their respective glomeruli, allowing for lateral excitation ([@B32]). Cx36 channels help to amplify an odorant signal sent from the sensory neurons onto the mitral cells by having depolarization spread from one mitral cell to the other neurons coupled to it ([@B32]). Cx36 channels were confirmed to be involved in mitral cell lateral excitation, because Cx36 knock-out mice did not show lateral excitation of mitral cells within the same glomerulus ([@B32]).

Cx36 mRNA has a daily expression rhythm in the OB of the rat, with highest expression during nighttime and lowest expression during daytime ([@B37]), out of phase with DA release ([@B38]). This may imply that Cx36 gap junctions also play a role in the diurnal rhythm of olfactory acuity in rodents ([@B72], [@B69]). And, if DA plays a role in uncoupling Cx36 channels of the mitral cells, as it does in inhibiting glutamate release from mitral cells ([@B39]), then DA may further dampen an odor signal being sent from a mitral cell by inhibiting lateral excitation among mitral cells.

The Olfactory Bulb Maintains its Own Daily Rhythms
--------------------------------------------------

Increasing evidence suggests that the OB may function as an independent circadian system controlling daily changes in olfaction ([@B119]). For example, the OB exhibits intrinsic circadian rhythms in firing rate and clock gene (*Per1*) activity *in vitro* ([@B71]). Interestingly, daily rhythms in the OB and olfactory discrimination persist when circadian rhythms are eliminated in the SCN ([@B1]) or when the SCN is ablated ([@B70]). A later study from this group showed that daily rhythms in olfactory discrimination in mice depend on clock gene expression but not the SCN ([@B69]), while the SCN is still necessary for entrainment of the OB in the intact animal ([@B70]). More recently, this group showed that VIP regulates circadian rhythms in gene expression and odor detection performance in the OB ([@B119]). Data from our lab suggesting diurnal variations in DA release in the OB ([@B38]) raise the possibility of circadian activity of dopaminergic cells in the OB as well ([@B118]).

Dopamine in the Human Olfactory Bulb
------------------------------------

Dopamine's presynaptic mechanism of inhibiting glutamate release from the OSNs in turtles and mice ([@B16]; [@B56]) also may be present in the human OB, since human OBs have been shown to have dopaminergic neurons in the GL ([@B3]). Interestingly, when labeling postmortem human brains with the TH antibody, it was shown that younger (35 years and under) postmortem OBs had less TH-positive cells than older (50 years and over) postmortem OBs ([@B3]). Rodents also show an increase in OB dopaminergic neurons with age ([@B98]). This increase in dopaminergic neurons in older OBs may be caused by the progression of PD, as discussed below.

[@B3] have proposed that younger people tend to detect odors better than older people (confirmed previously by [@B51]), because the over suppression of olfactory information processing by DA presynaptically inhibits the release of glutamate from OSNs onto mitral cells in older people ([@B50]; [@B3]). Although this presynaptic DA action is proposed to sharpen odor detection by filtering noise ([@B16]; [@B56]), an increase in DA OB neurons may suggest excessive DA activity. Based on the previous cited evidence ([@B56]; [@B39]), excessive DA activity could lead to a saturation of D~2~ receptor activation, which would not only block odor signal transmission by inhibiting glutamate release, but also by potentially uncoupling Cx36 channels between coupled mitral cell dendrites.

Parkinson's Disease and the Olfactory Bulb
------------------------------------------

Patients with PD often have types of olfactory dysfunction ([@B49]), which can be an early precursor to the development of PD ([@B140]). Close relatives of patients with idiopathic PD are much likelier to develop idiopathic PD and bradykinesia if they have hyposmia (a diminished sense of smell) but not normosmia (normal sense of smell) ([@B15]; [@B132]). These and other clinical studies provide evidence that non-motor smell tests are superior diagnostic tools for PD to motor tests, especially in people with mild PD who have yet to develop bradykinesia ([@B20]). Non-motor smell tests may serve as predictors of those who will develop PD ([@B15]; [@B132]).

How are the endogenous DA neurons of the OB affected by PD? Paradoxically, unlike the midbrain and, potentially, the retina, DA and TH neurons *increase* in the OBs of patients with PD ([@B84]; [@B121]). An increase in dopaminergic OB neurons has also been shown in the transgenic rat line, α-synuclein, which exhibit signs of olfactory dysfunction that precede signs of motor dysfunction ([@B102]). An increase in DA in the OB can contribute to hyposmia of PD patients ([@B84]) by increasing DA binding to D~2~ receptors located on OSNs and M/TCs, causing a presynaptic inhibition of glutamate release from the OSNs and M/TCs, effectively inhibiting odor performance ([@B83]; [@B16]; [@B56]; [@B39]). This hypothesis is supported by a study in which administration of the D~2~ agonist, quinpirole, caused a dose-dependent decrease in odor detection and performance in rats ([@B50]). Knockout mice lacking the dopamine transporter or D~2~ receptors have also been shown to have an odor discrimination deficit ([@B155]).

Midbrain's Substantia Nigra Pars Compacta and Ventral Tegmental Area
====================================================================

The striatum (a collective term for the caudate nucleus, NAcc, and the putamen of the basal ganglia) receives a large input from the SNc's dopaminergic neurons through the nigrostriatal pathway. This dopaminergic input results in the facilitation of movement through direct (D~1~ receptor-driven) and indirect (D~2~ receptor-driven) pathways (see Figure 1 in [@B125]). In addition to D~1~ and D~2~ receptors, the D~3~ receptor is expressed in the striatum (most heavily in the NAcc), the SN, and VTA (see [@B11]). The D~4~ and D~5~ receptors also show minimal expression in the SN (see [@B11]). The D~2~ receptor pathway appears to be especially important for driving the expression the clock protein PER2 in the dorsal striatum ([@B82]). Therefore, DA may be important in modulating circadian activities of the striatum, including daily locomotion, something that is lost in patients with PD.

The midbrain also contains the VTA, from which DA neurons project to different brain areas, including cortical (mesocortical projections) and limbic (mesolimbic projections) areas ([@B142]). Dopaminergic neurons in the mesolimbic pathway (often called the reward pathway, see Figure 1 in [@B142]) project to the hippocampus, NAcc, and the amygdala, are important for learning and motivation, and are well known to be influenced by drugs of abuse. In fact, prolonged exposure to cocaine in mice increases the expression of *Per1* and *Clock* mRNA, and it decreases the expression of *Per2*, *Bmal1*, *Cry1*, and *NPAS2* (a paralog of *Clock*) mRNA in the striatum ([@B158]). Cocaine may lead to addictive behaviors by altering the expression of circadian genes in the striatum ([@B158]) by increasing DA activity from the midbrain.

Dopamine Receptors' Effects on Clock Gene and Protein Expression in the Striatum
--------------------------------------------------------------------------------

The striatum receives a large dopaminergic input, and so it is not surprising that clock genes and proteins have various interactions with DA. Cultured mouse striatal neurons have been shown to express genes for DA receptors 1, 2, and 3, as well as for clock genes *Per1*, *Clock*, *Bmal1*, and *NPAS2* ([@B86]). These DA receptors differently regulate the expression of these clock genes. Application of the D~1~ receptor agonist, SKF-38393, increased mRNA levels of all of the above-mentioned clock genes, while the D~2~ receptor agonist, quinpirole, decreased *Clock* and *Per1* mRNA levels ([@B86]). Additionally, quinpirole injections were shown to increase nighttime expression of PER1, but decrease the protein's daytime expression ([@B86]). The following 2010 study by [@B82] shows that the D~2~ receptor is necessary for proper PER2 expression.

In the rat's dorsal striatum, the expression of PER2 peaks during the daytime hours, while extracellular DA peaks during the nighttime hours ([@B82]). Lesioning DA neurons via a unilateral injection of 6-hydroxydopamine significantly decreased the ipsilateral dorsal striatum's PER2 protein and mRNA expression 14 days after the injection, without evidence of restoration ([@B82]). Injections of α-methyl-*para*-tyrosine (AMPT), an inhibitor of TH, decreased DA content and daytime (ZT 1) PER2 expression, but increased PER2 expression during nighttime (ZT 13) ([@B82]). Lastly, the D~2~ receptor antagonist, raclopride, injected chronically, decreased PER2 expression at ZT 1, while the agonist quinpirole restored and reversed the daily PER2 expression in rats previously treated with 6-hydroxydopamine on the lesioned side ([@B82]).

Daily Tyrosine Hydroxylase and Dopamine Activity in the Midbrain
----------------------------------------------------------------

The expression of VTA's TH and the firing of dopaminergic neurons are both linked to a specific time of the day ([@B165]; [@B34]; [@B45]; [@B150]). Interestingly, the diurnal variation in VTA's TH protein expression appears to out-of-phase with the *TH* mRNA expression ([@B150]). TH in the VTA is expressed more during the daytime (around ZT 6) than during the nighttime (ZT 13-24), while *TH* mRNA is expressed less during the daytime (ZT 4) than the nighttime (ZT 16, 20) ([@B165]; [@B150]). Circadian expression of *TH* mRNA in the VTA is also low during the subjective day (CT 8 and 12) and high during the subjective night (CT 20 and 24) ([@B34]). Additionally, TH expression appears to be similar in the VTA and SNc, where both show peak expression at CT 0 and lowest expression at CT 12 ([@B34]). However, TH expression in the VTA and NAcc is out-of-phase, with both the peak for VTA TH expression and the trough for the NAcc TH expression occurring at ZT6 ([@B165]).

Tyrosine hydroxylase expression in the VTA is suppressed by CLOCK ([@B114]; [@B150]) and by the circadian nuclear receptor REV-ERBα ([@B34]). Homozygous *Clock* mouse mutants have an increased expression of TH in their VTA ([@B114]). Higher VTA expression of TH would cause an increase in DA production and release in the mesolimbic pathway, likely being one of the causes for the reported results of *Clock* mutant mice finding cocaine more rewarding and expressing higher sensitization to cocaine ([@B114]). *Rev-erb*α knock-out mice exhibited increased *TH* mRNA expression and DA release at CT 12 ([@B34]). Increased TH and DA through loss of REV-ERBα led to increased mania-like behavior in these mice ([@B34]).

Monoamine oxidase A (MAOA), an enzyme that suppresses DA activity by removing DA's amine group, is also controlled by circadian mechanisms. Midbrain's MAOA function is highly important in regulating DA activity and, therefore, mood and movement. MAOA and its mouse gene variant, *Maoa*, were found to have rhythmic expression in the VTA, with highest expression at ZT 6 and lowest at ZT 18 ([@B75]). Conversely, *Per2* mutant mice had a flat daily expression of *Maoa* and MAOA activity, which unsurprisingly led to higher levels of DA release and activity ([@B75]). *Per2* mutants also experienced less helplessness in a forced swim test compared to control mice, likely a result of increased DA due to decreased MAOA ([@B75]). The daily rhythmic expression of TH and MAOA may be a mechanism of daily mood fluctuation in people.

The firing activity of VTA neurons, as electrophysiology data show, does not appear to be consistent throughout studies ([@B34]; [@B45]; [@B150]). *In vivo* recordings from DA neurons in the VTA showed that these neurons fire the most spikes during the onset of daytime (7:00--11:00 h) and onset of nighttime (19:00--23:00 h), while firing significantly less spikes in between (11:00--15:00 h and 23:00--3:00 h) ([@B45]). Therefore, a 12-h period for the spike firing frequency is shown in these VTA neurons ([@B45]). However, other *in vivo* recording data show a steady firing rate of VTA neurons ([@B34]; [@B150]). This discrepancy may be due to inherent species difference, since the twice-daily highest spiking frequency was found in rats ([@B45]) and the steady firing frequency was recorded in mice ([@B34]; [@B150]). It may not be surprising that both CLOCK and REV-ERBα suppress VTA firing, as they also suppress TH expression ([@B114]; [@B34]; [@B150]). Mutant mice without a functional *Clock* have higher bursts and firing rates ([@B114]; [@B150]), while an antagonist of REV-ERBα, SR8278, increased the firing rate of VTA neurons equally during two different time points (ZT 1 and 11) ([@B34]).

Dopamine's Presynaptic Inhibition of Glutamate Release onto the Ventral Tegmental Area
--------------------------------------------------------------------------------------

Similar to the effect of DA on olfactory-nerve-evoked responses in OB neurons ([@B83]; [@B16]; [@B56]), VTA's DA inhibits glutamate release presynaptically via the D~2~ receptor ([@B95]). Focal stimulation within the VTA in the presence of various pharmacological blockers evoked non-NMDA EPSCs in dopaminergic neurons ([@B95]). Addition of exogenous DA inhibited these EPSCs ([@B95]). Repeating these experiments with the D~2~ receptor agonist, quinpirole, produced similar results in both the VTA and OB, indicating that this inhibition is specific to D~2~ receptors ([@B83]; [@B16]; [@B95]; [@B56]). DA also reduced the frequency of spontaneous miniature EPSCs in VTA neurons without affecting their mean amplitude, suggesting that the inhibitory effects of DA are presynaptic ([@B95]).

Dopamine and GABA Co-release from Midbrain Dopaminergic Neurons
---------------------------------------------------------------

Midbrain VTA and SNc DA neurons provide input onto the striatum that is not strictly dopaminergic. Midbrain DA neurons have been shown to co-release DA and GABA onto medium spiny neurons of the striatum ([@B156]; [@B21]; [@B33]; [@B159]). This co-release produces a large GABA~A~ current that inhibits medium spiny neurons ([@B156]). Interestingly, these dopaminergic neurons package GABA into vesicles via the vesicular monoamine transporter 2, a traditional DA transporter, and not by the vesicular GABA transporter ([@B156]).

Cholinergic interneurons in the NAcc core also receive a heterogeneous input from the midbrain ([@B33]). Those neurons receive dopaminergic and GABAergic input from the midbrain DA neurons, causing hyperpolarization via the D~2~ and GABA~A~ receptors, respectively ([@B33]). However, cholinergic interneurons in the NAcc medial shell do not receive GABAergic input from midbrain dopaminergic neurons ([@B33]). This heterogeneity of midbrain's dopaminergic input to the NAcc and dorsal striatum could be involved with reward-related learning ([@B33]).

Gap Junctions in the Midbrain's Dopaminergic and GABAergic Neurons
------------------------------------------------------------------

As with all other dopaminergic brain areas discussed in this review, the midbrain is also rich in gap junctions ([@B153]; [@B160]; [@B4]). Within the VTA, GABA neurons are strongly coupled to each other via Cx36 gap junctions ([@B153]), with an estimate of 2,000 channels per cell ([@B4]). The presence of Cx36 was confirmed with quantitative reverse transcription polymerase chain reaction, immunohistochemistry, and by the reduction of spiking after the application of the Cx36 specific blocker, mefloquine ([@B4]). It was suggested that VTA GABA neurons, not VTA DA neurons, express Cx36 channels, due to the fact that GABA VTA neurons have a different electrophysiological profile from DA neurons ([@B4]). However, recent evidence may imply that these GABA VTA neurons also express DA, because it was shown that VTA, as well as SNc, projection neurons express both DA and GABA ([@B156]; [@B33]). In the SNc of rat pups, gap junctions are expressed differently during postnatal development ([@B160]). For example, it was found that 40% of neurons from rats aged between P5 and P10 were coupled, that no neurons were coupled between the ages of P10 and P15, and that 17% of neurons were coupled between the ages of P10 and P15 ([@B160]). It would be informative to test for Cx36 and vesicular monoamine transporter 2 immunoreactivity in the VTA to confirm whether VTA DA neurons also express Cx36 gap junctions and also to observe how gap junction coupling changes later in rodent development.

Parkinson's Disease and the Midbrain and Striatum
-------------------------------------------------

The degeneration of the dopaminergic neurons in the SNc is the most well-known cause of motor symptoms in PD, including bradykinesia ([@B28]). However, increasing evidence suggests that midbrain DA loss in patients with PD could lead to motor and non-motor circadian dysfunction. As mentioned in the section "Introduction," there are a number of limitations to neurotoxin-based and transgenic animal models of PD (see [@B60]). One exception is the transgenic MitoPark Parkinsonian mouse, which has been shown to develop progressive cellular and motor alterations analogous to those seen in idiopathic PD, including a gradual loss of midbrain (e.g., VTA and SN) dopaminergic neurons ([@B55]; [@B64]; [@B60]).

This MitoPark mouse was used to study the rest/wake activities and locomotion throughout the progression of PD in the mouse's lifetime ([@B60]). To assess daily rest and locomotor activity, as well as how lighting could affect these activities, extensive entrainment periods of light and dark conditions were used ([@B60]). These entrainment periods lasted for several weeks and showed evidence of the age-related degeneration of dopaminergic neurons with progression of the disease ([@B60]).

Prior to the onset of PD, 11-week-old MitoPark mice entrained well to the 12-h:12-h light-dark cycle, and when exposed to a 1 h light pulse and then released into constant darkness, showed a phase delay of activity that was comparable to that in their control counterparts ([@B60]). However, by age 26 weeks, when DA levels in the nigrostriatal regions of the MitoPark mouse have been shown to be decreased ([@B64]), the locomotor activity of MitoPark mice had become completely arrhythmic when the mice were re-assessed under constant darkness ([@B60]). MitoPark mice also lost circadian control of locomotor activity when exposed to constant, bright light ([@B60]). However, over the experiment's duration, the daily rhythm of rest/activity in a light-dark cycle in MitoPark mice was maintained ([@B60]).

In addition to motor symptoms, PD is associated with non-motor symptoms involving loss of midbrain DA. Patients with PD often experience dysfunction of REM sleep ([@B30]), which appears to be regulated by dopaminergic neurons in the SNc ([@B105]). In an MPTP rat model of PD, a strong correlation was found between the number of SNc DA neurons lost and the percentage decrease in REM sleep ([@B105]). Patients with PD may develop RBD, which is characterized by the enacting of dreams, often with flailing of the limbs ([@B30]; [@B162]). RBD has been shown to be present in nearly 25--50% of people with PD, and it is often a precursor to PD ([@B30]; [@B104]).

Degeneration of the dopaminergic neurons in the midbrain's SNc in patients with PD is also important to the striatum, as SNc dopaminergic neurons project to the striatum via the nigrostriatal pathway. TH, DA, and its metabolites, DOPAC and HVA, show daily rhythms of expression in the striatum ([@B29]; [@B165]), where DA regulates rhythms of clock gene and protein expression ([@B86]; [@B82]; [@B73]). In patients with PD, reduced DA input to the striatum due to nigrostriatal degeneration could blunt daily rhythms of clock gene expression and contribute to circadian disruptions ([@B162]; [@B161]). IPT-SPECT imaging data suggest that reduced striatal dopamine transporters may contribute to the pathophysiology of RBD ([@B54]). Another sleep disorder found in patients with PD is RLS, with a reported prevalence of 8--50% ([@B162]). Some imaging (PET) data support the hypothesis that disturbed striatal dopamine transmission is involved in the pathophysiology of RLS ([@B157]).

Hypothalamus
============

One site for DA's unique, circadian-like neuromodulatory activities is within the arcuate nucleus of the hypothalamus (see Figure 4 in [@B62]; [@B18]). There, DA regulates the daily rhythm of PRL, a hormone best known for its involvement with milk production in mammals, from the lactotrophs of the anterior pituitary gland ([@B62]; [@B18]). An essential role of the PRL rhythm is the maintenance of the corpus luteum and its release of progesterone during pregnancy in rodents ([@B62]; [@B18]). Therefore, DA also plays a role in the regulation of reproductive mechanisms. There are several DA neuronal subpopulations in the hypothalamus, at least three of which contribute to the inhibition of PRL release: TIDA, tuberohypophyseal dopamine neurons, and periventricular hypophyseal dopamine neurons ([@B66]). Additional data from this lab suggest that clock gene expression, particularly *Per1* and *Per2*, within TIDA neurons may regulate the daily rhythmicity of DA release from these neurons in ovariectomized rats ([@B146]; [@B145]). This section focuses on the potential of TIDA neurons to regulate the circadian rhythms of PRL release and potential disruptions to PRL release in patients with PD. In regard to DA receptors, the arcuate nucleus expresses D~1~ and D~2~ receptors ([@B139]), and potentially D~3~ receptors on TIDA neurons ([@B106]).

This section also discusses the role of DA in the SCN, the site of the master clock. Interestingly, in one study, TH-positive neurons were labeled within the SCN of neonatal hamsters ([@B154]). The SCN expresses D~1~ and D~5~ receptors ([@B137]), where DA from other brain regions exerts feedback effects ([@B118]). Finally, this section reviews potential links between PD and the SCN, including mixed results of animal studies implicating SCN involvement.

Dopamine from TIDA Neurons and the Regulation of Prolactin Release
------------------------------------------------------------------

The TIDA neurons of the hypothalamus' arcuate nucleus display a rhythmic release of DA, which is out of phase with PRL release ([@B62]; see Figure 2 in [@B18]). In humans, PRL release is high in the nighttime and low in the daytime, and DA release drops before the release of PRL ([@B62]; [@B18]). Therefore, TIDA DA release inhibits pituitary lactotrophs, decreasing PRL release ([@B62]; [@B18]). However, PRL also stimulates the activity of TIDA neurons, thereby increasing DA release ([@B62]; [@B18]). These feedback mechanisms can result from artificial cervical stimulation, which results in PRL being released twice per day, at 300 and 1700 h, and likely later in the day, while DA is released at around 1200 h ([@B62]; [@B18]). This twice-daily and daily release of PRL and DA, respectively, continues for a few days without additional cervical stimulation, potentially showing evidence of a circadian-like neuronal "memory" that drives the expression of PRL days after stimulation ([@B62]; [@B79]; [@B18]). It is thought that this memory regulates the rhythms of DA and PRL ([@B62]; [@B79]; [@B18]).

GABA release from Hypothalamic Tuberoinfundibular Dopamine Neurons
------------------------------------------------------------------

Amongst other dopaminergic neuronal populations of the arcuate nucleus, TIDA neurons appear to also release GABA ([@B169]). GABA release from the arcuate nucleus may inhibit PRL release ([@B112]) and other neurons (including TIDA) of the arcuate nucleus, as well ([@B169]). By using optogenetics, [@B169] activated DA neurons of the arcuate nucleus while recording from other arcuate neurons, both TIDA and non-TIDA neurons. Recordings showed a large-amplitude, inward (depolarizing) current with fast decay, followed by a small-amplitude, outward (hyperpolarizing) current with slow decay ([@B169]). This outward current was determined to be a GABA~A~ current, since it was blocked by the GABA~A~ antagonist bicuculline ([@B169]). Therefore, TIDA neurons also release GABA, which hyperpolarizes neurons in the arcuate nucleus, and, potentially, the lactotrophs of the anterior pituitary ([@B112]; [@B169]). GABA release from TIDA neurons onto other arcuate nucleus neurons may help to keep hypothalamic DA activity low until 1200 h in cervically stimulated rats ([@B79]), and it may contribute to the circadian rhythmic activity in the hypothalamus.

SCN and Role of Dopamine
------------------------

The SCN, located above the optic chiasm, maintains mammalian circadian rhythms by being entrained by light it receives through the retinohypothalamic tract and by entraining the rhythms of peripheral regions. Within neurons of both the SCN and periphery, 24-h oscillations are generated through a clock gene transcriptional and translational feedback loop ([@B108]). DA is relevant to the SCN, as the main SCN clock communicates timing information with other brain clocks to regulate DA activity, and DA also appears to have feedback effects on the SCN ([@B118]).

A role for dopaminergic modulation of SCN-related circadian rhythmicity is suggested by the presence of D~1~ and D~5~ receptors in the SCN ([@B137]). In fact, DA may be necessary to entrain the developing, fetal SCN ([@B118]). Prenatal exposure to the D~1~ receptor agonist, SKF38393, disrupts the expression of c-fos (a marker of neuronal activity) in the neonatal SCN ([@B58]). Light pulses also mimic the effects of D~1~ receptor activation in neonatal hamsters, suggesting that maternal DA represents daytime to the fetal SCN ([@B163]).

Recent evidence that methylphenidate alters the electrical firing rate and clock gene expression in the SCN ([@B6]; [@B9]; [@B118]) suggests that some drug-induced changes in DA neurotransmission also may influence SCN clock activity. Data from mostly animal models of PD (see below), implicating dopamine in SCN dysfunction, are mixed, but suggest that DA depletion may affect circadian rhythm mechanisms differently in the SCN than in peripheral hypothalamic areas.

Parkinson's Disease and the Hypothalamus
----------------------------------------

The proposed idea that PD is disruptive to circadian rhythms would be central to the functioning of the hypothalamus, where the SCN resides. Mechanisms underlying circadian fluctuations in signs and symptoms in patients with PD remain unclear, although altered DA metabolism and DA receptor downregulation have been implicated ([@B162]). Sites of disruption may be along afferent pathways to the SCN (e.g., impaired light transmission due to dopaminergic retinal degeneration), within the SCN itself (e.g., altered clock gene expression), or within downstream peripheral efferent pathways (e.g., altered output) ([@B162]).

Data from mostly animal models implicating SCN dysfunction in PD is mixed. Clock gene and protein expression in the SCN is unaffected in some animal models of PD, but is affected in others. For example, studies have shown that the photoresponse of the SCN is unaltered in D~2~ receptor knockout mice, but masking (which could hide potential SCN dysfunction by exposing a nocturnal animal to light) was abolished in these mice ([@B44]). The expression of *Per2* and PER2 in the SCN is unaffected in some Parkinsonian animal models ([@B73]; [@B101]). In addition, the rhythmic release of melatonin and cortisol (a function regulated by the SCN) is unaffected in Parkinsonian non-human primates ([@B60]; [@B61]), which mirrors a finding that nighttime melatonin release in PD patients was similar to that of control patients ([@B59]). While these findings suggest that the central rhythms of the SCN are unaffected in some models and patients of PD, other studies may contradict this notion.

The SCN of a Parkinsonian rat model (symptoms were induced by rotenone administration) displayed increased levels of expression of *Per2* at some time points, varying levels of expression of *Cry2* at different time points, and reduced levels of expression of *Per1* and *Bmal1* at some time points ([@B111]). In addition, the daily pulse of *Per1*, *Per2*, *Cry1*, *Cry2*, and *Bmal1* was significantly decreased in the SCN of the rotenone-induced PD rat model ([@B111]). In a Parkinsonian mouse model (initiated by the administration of MPTP), the levels of *Bmal1, Cry1, Dec1*, and *Rev-erb*α in the SCN were significantly decreased at some time points ([@B78]). The finding of normal PER2 expression in the SCN, but altered electrical output from the SCN, in a Parkinsonian (α-synuclein overexpressing) transgenic mouse further suggests disordered function or synchrony in the SCN ([@B101]; [@B123]). Therefore, the extent to which PD affects the SCN, and through which mechanisms, remains unclear.

MTPT-treated mice also had significantly lower locomotor activity during nocturnal hours and lower body temperatures (implying the involvement of the hypothalamus) during daytime and nighttime hours compared to the control mice ([@B78]). Peripheral hypothalamic areas, including the periventricular nucleus, demonstrate decreased expression of PER2 after the depletion of DA neurons with 6-hydroxydopamine ([@B73]). This suggests that DA depletion can affect circadian rhythm mechanisms differently in the SCN than in peripheral hypothalamic areas.

Hypothalamic DA neurons are also affected in PD, as is evidenced by both a 50% decrease in DA neurons in postmortem brains of PD patients ([@B36]) and a decrease in DA levels of hypothalamic extracts from PD patients compared with control subjects ([@B130]). A PET study also showed a significant decrease in D~2~ receptor availability in the hypothalami of PD patients compared to that in control subjects ([@B131]). Hypothalamic DA degeneration may be related to the progression of PD, but earlier stages of the disease may not affect DA significantly. For example, plasma PRL levels of patients with early stages of idiopathic PD were not significantly different from the levels of the age-matched controls ([@B8]), implicating proper function of DA from TIDA neurons. Conversely (and strange when considering that DA reduction should increase PRL levels), other patients with PD have shown significantly lower levels of plasma PRL ([@B122]; [@B166]). Yet again, other PD patients have shown an increase in nocturnal PRL ([@B13]). These results provide evidence that hypothalamic DA neurons are affected with the progression of PD, with clear implications to normal circadian rhythms and potential disruption of PRL cycling. However, the exact mechanism as to how TIDA and other hypothalamic DA neurons are affected by the progression of the disease is not clear.

Discussion
==========

Circadian rhythms synchronize nearly every daily biological process -- from gene transcription to behavior -- and evidence of DA's importance in the modulation of circadian rhythms is becoming more apparent. DA has been shown to have circadian-like activities in the retina, OB, striatum, midbrain, and hypothalamus, where it regulates, and is regulated by, clock genes in some of these areas. The various neuronal and molecular mechanisms reviewed here, and the mounting evidence that neurodegenerative diseases such as PD influence circadian rhythms, show that DA has both direct and indirect impacts on some of the circadian rhythms of the SCN and these peripheral brain areas (see Supplementary Table [1](#SM1){ref-type="supplementary-material"}).

Summary of Dopamine's Involvement in Parkinson's Disease and Associated Circadian Dysfunction
---------------------------------------------------------------------------------------------

In addition to causing classic motor symptoms, reduced midbrain DA has been shown to disrupt circadian control of locomotor activity ([@B60]) and REM sleep ([@B105]) in PD. Reduced DA in the striatum due to nigrostriatal degeneration could contribute to RLS, blunt clock gene expression, and disrupt circadian rhythms in patients with PD ([@B157]; [@B162]; [@B161]).

Reduced DA levels in the retina observed in patients with PD ([@B126]; [@B76]; [@B2]) may contribute to visual symptoms (see [@B7]) and impair light adaption ([@B134]). As DA modulation of ipRGCs is involved in photic entrainment of the SCN ([@B68]; [@B143]), decreased retinal DA levels associated with PD may disrupt circadian rhythms.

Patients with PD often experience early olfactory dysfunction ([@B49]; [@B140]; [@B48]). Some olfactory dysfunction is linked to pathology and increased TH and DA levels in the OB ([@B41]; [@B84]; [@B121]), which may impair odor detection ([@B50]; [@B84]) and odor discrimination ([@B155]) via actions at D~2~ receptors ([@B50]; [@B83]; [@B16]; [@B56]; [@B39]).

Mechanisms underlying circadian disruptions in PD remain unclear, but may involve afferent pathways to the SCN (e.g., impaired light transmission due to dopaminergic retinal degeneration) ([@B76]; [@B2]), the SCN itself (e.g., altered clock gene expression) ([@B78]; [@B111]), or downstream peripheral efferents (e.g., altered electrical output from the SCN) ([@B101]; [@B162]; [@B123]). DA from other brain regions may exert feedback effects in the SCN via actions at D~1~ and D~5~ receptors ([@B137]; [@B118]). Patients with PD have altered levels of PRL ([@B122]; [@B13]; [@B166]), suggesting disruptions in PRL cycling involving TIDA neurons ([@B62]; [@B18]).

New Directions in Research
--------------------------

New research should continue to explore how DA, as well as other neurotransmitters, affect(s) the circadian rhythms of the retina, OB, striatum, midbrain, and hypothalamus. Neurotransmitters serotonin and norepinephrine should also be studied, since the raphe nuclei and locus coeruleus neurons project throughout the brain (including the rat OB; [@B149]; [@B116]), and the activity of both transmitters fluctuates between sleep and wake cycles ([@B128]; [@B38]). Melatonin, a hormone that helps to induce sleep during darkness and regulates the release of DA in the retina ([@B52]), should continue to be studied in other brain areas to clarify how it interacts or regulates the other neurotransmitters. In addition to the brain areas discussed here, the circadian rhythms of other brain areas also may be influenced by DA's activity. For example, the hippocampus receives a large dopaminergic input from the VTA via the mesolimbic pathway, and this input may regulate clock genes and proteins ([@B113]), which could be involved in hippocampus-dependent learning ([@B87]) and could protect against hippocampal cell death ([@B23]; [@B138]; [@B22]).

Conclusion
==========

Circadian rhythms drive the daily biological processes, which in turn drive our daily lives. Disruptions in circadian rhythms -- which can result from PD and other disorders as well as from environmental influences -- can lead to various health risks and disorders ([@B144]; [@B151]; [@B43]; [@B46]; [@B115]). As our understanding of how DA affects and is affected by circadian rhythms grows, new diagnostic methods (such as detection of hyposmia or anosmia as a precursor to circadian disruption) and pharmacologic tools may be developed to help those afflicted with disorders of circadian rhythms.
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AC

:   adenylate cyclase

AC1

:   adenylate cyclase isoform 1

AHr

:   aryl hydrocarbon receptor

CRY

:   cryptochrome (clock gene and protein variant)

CT

:   circadian time

Cx36

:   Connexin 36 (gap junction channel)

D~1,2,3,4,5~

:   dopamine receptors 1, 2, 3, 4 and 5

DA

:   dopamine

DOPAC

:   3,4-Dihydroxyphenylacetic acid

EPSC

:   excitatory postsynaptic current

ETC

:   external tufted cell (olfactory bulb)

GL

:   glomerular layer (olfactory bulb)

HVA

:   homovanillic acid

ipRGC

:   intrinsically photosensitive retinal ganglion cells

JGCs

:   juxtaglomerular cells (olfactory bulb)

M/TCs

:   mitral/tufted cells (olfactory bulb)

MPTP

:   1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (neurotoxin that induces Parkinson's-like symptoms)

NAcc

:   nucleus accumbens

NPAS2

:   neuronal PAS domain-containing protein 2 (clock gene and its protein variant)

OB

:   olfactory bulb

ONL

:   olfactory nerve layer (olfactory bulb)

OSN

:   olfactory sensory neuron (olfactory bulb)

P

:   postnatal day

PD

:   Parkinson's disease

PER

:   period (clock gene and protein variant)

PET

:   positron emission tomography

PGC

:   periglomerular cell

PKA

:   protein kinase A

PRL

:   prolactin

RBD

:   REM sleep behavior disorder

REM

:   rapid-eye movement

RGC

:   retinal ganglion cells

RLS

:   restless leg syndrome

SAC

:   short axon cell (olfactory bulb)

SCN

:   suprachiasmatic nucleus

SN

:   substantia nigra (pars compacta and pars reticulata)

SNc

:   substantia nigra pars compacta

TH

:   tyrosine hydroxylase

TIDA

:   tuberoinfundibular dopamine neurons (hypothalamus)

VIP

:   vasoactive intestinal polypeptide

VTA

:   ventral tegmental area

ZT

:   Zeitgeber time.
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